Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-CTNNB1 Antibody (R3J68)

Catalog #:   RHE07609 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM, IHC, WB
Accession: P35222
Overview

Catalog No.

RHE07609

Species reactivity

Human, Mouse, Rat, Monkey

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IHC: 1:200-1:1000, WB: 1:500-1:2000

Target

CTNNB, Catenin beta-1, CTNNB1, Beta-catenin

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P35222

Applications

ELISA, FCM, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3J68

Data Image
  • Flow Cytometry
    Flow cytometric analysis of HepG2 cells using CTNNB1 mouse mAb (green) and negative control (red).
  • Flow Cytometry
    Flow cytometric analysis of A549 cells using CTNNB1 mouse mAb (green) and negative control (red).
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CTNNB1 mouse mAb with DAB staining.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human rectal cancer tissues using CTNNB1 mouse mAb with DAB staining.
  • Western blot
    Western blot analysis using CTNNB1 mouse mAb against Hela (1), HepG2 (2),NIH3T3 (3),MCF-7 (4), C6 (5),COS-7 (6),K562 (7),Jurkat (8), A549 (9),SH-SY5Y (10),BEL-7402 (11), HEK293 (12), and HEK293-6e (13) cell lysate.
  • Western blot
    Western blot analysis using CTNNB1 mouse mAb against Hela (1), HepG2 (2),NIH3T3 (3),MCF-7 (4), C6 (5),COS-7 (6),K562 (7),Jurkat (8), A549 (9),SH-SY5Y (10),BEL-7402 (11), HEK293 (12), and HEK293-6e (13) cell lysate.
References

Basal cell adenoma with S100 protein-positive "stroma": a distinct triphasic salivary gland neoplasm characterized by CTNNB1 mutation., PMID:40515848

[Morphomolecular subtyping of hepatocellular adenoma]., PMID:40471284

Novel Aptamers Targeting Sclerostin Loop3 Improve Skeletal and Muscle Properties Without Adverse Cardiovascular Effects in Orchiectomized Mice., PMID:40464222

Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758

Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers., PMID:40442146

Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma., PMID:40211365

Transcription factor KLF5 regulates MsrB1 to promote colorectal cancer progression by inhibiting ferroptosis through β-catenin., PMID:40210135

EMMPRIN Correlated with β-CATENIN in Various t Stages of Colorectal Adenocarcinoma., PMID:40156418

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies., PMID:40154481

Bisphenols exposure at environmentally relevant dose promoted ovarian cancer progression and modulated tumor microenvironment through β-catenin/SPP1 axis., PMID:40054195

Cancer-associated fibroblasts promote growth and dissemination of esophageal squamous cell carcinoma cells by secreting WNT family member 5A., PMID:39954174

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review., PMID:39931054

Multiplexed siRNA Immunoassay Unveils Spatial and Quantitative Dimensions of siRNA Function, Abundance, and Localization In Vitro and In Vivo., PMID:39829074

An immunohistochemical and molecular genetic study of 60 colorectal carcinoma brain metastases in pursuit of predictive biomarkers for cancer therapy., PMID:39824298

Tumor β-Catenin Expression Associated With Poor Prognosis to Anti-PD-1 Antibody Monotherapy in Non-small Cell Lung Cancer., PMID:39758230

Interplay between Netrin-1 and Norrin controls arteriovenous zonation of blood-retina barrier integrity., PMID:39693351

β‑catenin expression in endometrioid type endometrial cancer: Expression patterns and impact on disease outcomes., PMID:39421318

IGSF9 promotes tumor invasion and metastasis through GSK-3β/β-catenin mediated EMT in lung cancer., PMID:39383800

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab., PMID:39269823

TRPV4-β-catenin axis is a novel therapeutic target for dry skin-induced chronic itch., PMID:39218273

DRD4 promotes chemo-resistance and cancer stem cell-like phenotypes by mediating the activation of the Akt/β-catenin signaling axis in liver cancer., PMID:39174739

Exomic and epigenomic analysis of pulmonary blastoma., PMID:39121796

A novel drug prejudice scaffold-imidazopyridine-conjugate can promote cell death in a colorectal cancer model by binding to β-catenin and suppressing the Wnt signaling pathway., PMID:39067696

Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors., PMID:38986529

A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors., PMID:38823034

Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial., PMID:38685486

Ketohexokinase-A deficiency attenuates the proliferation via reducing β-catenin in gastric cancer cells., PMID:38614422

Association of the combined parameters including the frequency of primary cilia, PD-L1, Smoothened protein, membranous β-catenin and cytoplasmic β-catenin expression with the outcome of patients with clear cell renal cell carcinoma., PMID:38420990

Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial., PMID:38406172

Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report., PMID:38348622

β-CATENIN stabilizes HIF2 through lncRNA and inhibits intravenous immunoglobulin immunotherapy., PMID:37744383

HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers., PMID:37572797

Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer., PMID:37511664

β-catenin promotes resistance to trastuzumab in breast cancer cells through enhancing interaction between HER2 and SRC., PMID:37331014

Programmed cell death ligand-1 (PD-L1) expression in desmoid tumors: a retrospective study., PMID:37318496

The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis., PMID:37316937

The molecular pathogenesis of craniopharyngiomas., PMID:36748936

Netrin-1 binding to Unc5B regulates Blood-Retina Barrier integrity., PMID:36711611

A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy., PMID:36613564

Pancreatoblastoma in an elderly woman: A case report simulating a pancreatic neuroendocrine tumour with emphasis on cytomorphological features., PMID:36546760

Clinical Prognostic Factors and Integrated Multi-Omics Studies Identify Potential Novel Therapeutic Targets for Pediatric Desmoid Tumor., PMID:36539683

Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations., PMID:36379463

The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma., PMID:36150916

Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy., PMID:35884434

Tissue transglutaminase activates integrin-linked kinase and β-catenin in ovarian cancer., PMID:35810788

Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody., PMID:35793868

Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience., PMID:35711837

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma., PMID:35567547

Targeted Therapy in the Management of Modern Craniopharyngiomas., PMID:35468695

Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of β-catenin degradation., PMID:35418614

Datasheet

Document Download

Anti-CTNNB1 Antibody (R3J68).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-CTNNB1 Antibody (R3J68) [RHE07609]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only